ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD

KD025-213 Primary Analysis Topline Results

May 21st, 2020
This presentation contains “forward-looking” statements that are based on the beliefs and assumptions of, and on information currently available to, management of Kadmon Holdings, Inc. (the “Company”). All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include information concerning the initiation, timing, progress and results of clinical trials of the Company’s product candidates, the timing or likelihood of regulatory filings and approvals for any of its product candidates, and estimates regarding the Company’s expenses, future revenues and future capital requirements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q, all of which are filed with the Securities and Exchange Commission.

Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to conform any of the forward-looking statements to actual results or to changes in its expectations.
CEO Opening Remarks

Harlan W. Waksal, M.D., President and CEO
ROCKstar (KD025-213): Primary Analysis Outcomes

- Belumosudil (KD025) met the primary endpoint of Overall Response Rate (ORR) in the pivotal trial in cGVHD patients who have received 2 or more prior lines of systemic therapy:
  - 73% ORR with KD025 200 mg QD (95% CI: 60%, 83%)
  - 74% ORR with KD025 200 mg BID (95% CI: 62%, 84%)

- Responses observed across all key patient subgroups

- Durable responses
  - 49% of responders have maintained responses for ≥20 weeks
  - Median duration of response (DOR) has not yet been reached

- Well tolerated
  - AEs have been consistent with those expected in this patient population

CI: Confidence Interval
ROCKstar Primary Analysis Results

KD025-213: Pivotal Clinical Trial of Belumosudil (KD025) in cGVHD
Sanjay Aggarwal, M.D., Senior Vice President, Clinical Development
ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD

ROCKstar (KD025-213): A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

**Key Eligibility Criteria**
- Ages ≥12
- 2-5 prior lines of systemic therapy for cGVHD
- Systemic therapy for cGVHD is indicated

**Primary Endpoint:**
- ORR, per 2014 NIH criteria

**Key Secondary Endpoints:**
- Safety
- Duration of response (DOR)
- Lee Symptom Score (QoL measurement)
- Changes in corticosteroid and calcineurin inhibitor dose
- Failure-free Survival (FFS)
- Overall Survival (OS)

R Treat to clinically significant progression

KD025 200 mg QD (n=63)

KD025 200 mg BID (n=63)
ROCKstar: Statistical Analysis Plan

**Primary Endpoint: ORR**

Statistical significance is achieved if the lower bound of the 95% CI of ORR exceeds 30%

<table>
<thead>
<tr>
<th>Timepoint</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interim Analysis</td>
<td>2 months after completion of enrollment</td>
</tr>
<tr>
<td></td>
<td><em>Primary endpoint met at interim analysis</em></td>
</tr>
<tr>
<td></td>
<td>Data presented at TCT, February 2020</td>
</tr>
<tr>
<td>Primary Analysis</td>
<td>6 months after completion of enrollment</td>
</tr>
<tr>
<td></td>
<td>Topline data announced May 2020</td>
</tr>
<tr>
<td>1-year Follow Up</td>
<td>12 months after completion of enrollment</td>
</tr>
<tr>
<td></td>
<td>Available Q4 2020</td>
</tr>
</tbody>
</table>
# ROCKstar: Advanced Patient Population

## Demographics and Baseline Characteristics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>KD025 QD (n=66)</th>
<th>KD025 BID (n=66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age [years (range)]</td>
<td>53 (21-77)</td>
<td>57 (21-77)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>64</td>
<td>50</td>
</tr>
<tr>
<td>Median prior lines of therapy</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Median time from cGVHD diagnosis to enrollment (months)</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>NIH Severe cGVHD(^1) [n (%)]</td>
<td>45 (68%)</td>
<td>42 (64%)</td>
</tr>
<tr>
<td>Median prednisone dose (mg/kg/day)</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>≥4 organs involved [n (%)]</td>
<td>33 (50%)</td>
<td>35 (53%)</td>
</tr>
<tr>
<td>Prior ibrutinib treatment(^1)</td>
<td>22 (33%)</td>
<td>24 (36%)</td>
</tr>
<tr>
<td>Prior ruxolitinib treatment</td>
<td>20 (30%)</td>
<td>18 (27%)</td>
</tr>
<tr>
<td>Refractory to line prior to enrollment, excluding unknown / missing</td>
<td>80% (45/56)</td>
<td>64% (34/53)</td>
</tr>
</tbody>
</table>

\(^1\)Stratification factor
Belumosudil (KD025) achieved clinically and statistically significant ORRs in both arms

Complete responses observed in all affected organ systems

Four patients have achieved an overall complete response
ROCKstar Met Primary Endpoint

- Belumosudil (KD025) achieved clinically and statistically significant ORRs in both arms
- Complete responses observed in all affected organ systems
- Four patients have achieved an overall complete response

Threshold for success: 30%
Statistical significance is achieved if the lower bound of the 95% CI of ORR exceeds 30%
ROCKstar: Responses Observed Across All Key Subgroups

Pooled responses across arms, unless arms are stated.
ROCKstar: Durability of Response

- **Durable responses achieved with belumosudil (KD025):**
  - 49% of responders have maintained responses for ≥ 20 weeks
  - Median duration of response (DOR) has not yet been reached
  - ROCKstar durability data continue to mature

- **In earlier Phase 2a trial of belumosudil (KD025) in cGVHD (KD025-208) with a median follow-up of 2 years**\(^1\):
  - Median DOR of 35 weeks
  - 43% of patients have remained on belumosudil for >1 year
  - 28% of patients have remained on belumosudil for >1.5 years

---

\(^1\) Data as of February 19, 2020.
## ROCKstar: Safety and Tolerability

<table>
<thead>
<tr>
<th>Commonly Reported AEs, n (%)</th>
<th>KD025 QD (n=66)</th>
<th>KD025 BID (n=66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Grade, in ≥20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>26 (39)</td>
<td>16 (24)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>20 (30)</td>
<td>18 (27)</td>
</tr>
<tr>
<td>Nausea</td>
<td>17 (26)</td>
<td>17 (26)</td>
</tr>
<tr>
<td>Cough</td>
<td>19 (29)</td>
<td>13 (20)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>20 (30)</td>
<td>11 (17)</td>
</tr>
<tr>
<td>URTI</td>
<td>14 (21)</td>
<td>16 (24)</td>
</tr>
<tr>
<td>Liver-related investigations (SMQB)</td>
<td>12 (18)</td>
<td>16 (24)</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>17 (26)</td>
<td>11 (17)</td>
</tr>
</tbody>
</table>

- AEs were overall consistent with those expected in cGVHD patients receiving corticosteroids and other immunosuppressants
- No CMV infection or reactivation observed
- No significant drug-related cytopenias reported
ROCKstar Pivotal Trial: Primary Analysis Summary

- **Belumosudil (KD025) met the primary endpoint in pivotal trial in cGVHD:**
  - 73% and 74% ORR with belumosudil 200 mg QD and 200 mg BID, respectively
- **49% of responders have maintained responses for ≥20 weeks**
  - Median DOR has not yet been reached; durability data continue to mature
- **Well tolerated**
  - No CMV infection or reactivation observed
  - No significant drug-related cytopenias reported
- **Data to be submitted for presentation at an upcoming medical meeting**
Commercial Overview

Haya Taitel, RPh, Senior Vice President, Chief Commercial Officer
Significant cGVHD Market with Unmet Medical Needs

- Significant cGVHD market
  - 5,000 new cGVHD patients/year\(^1\)
  - 5-year overall survival of 55\%\(^2\)

- Unmet therapeutic needs
  - Steroids are standard of care in frontline treatment\(^1\)
    - 80% of cGVHD patients require additional treatment beyond initial therapy\(^3\)
    - Patients cycle through lines of therapy every 2-4 months\(^1\)

---

\(^1\) Bachier CR. et al. ASH Annual Meeting 2019, Abstract #2109.
Patients are Concentrated at Academic Transplant Centers

80% of cGVHD Patients are Treated at 70 Transplant Centers

Efficient Field Footprint

<15 total field associates to address cGVHD market

Top Allo-HCT center by volume

KD025-213 trial site

Dark green indicates higher allo-HCT volume

CIBMTR, 2014
Commercial Infrastructure in Place

Our efficient commercial model is optimized for profitable growth

Marketing & Sales
Market Access
Customer Service

Medical Affairs
Pharmacovigilance

Business Analytics
Commercial Finance

CMC
Supply Chain

Legal / Compliance

Regulatory Affairs
Quality Assurance

Kadmon Pharmaceuticals: Commercial operation based in Warrendale, PA
Components in Place to Launch and Commercialize KD025

- Concentrated Market
- Experienced Team
- Existing Commercial Infrastructure
- Strategic Launch Plan
Belumosudil in cGVHD: Path Forward

Harlan W. Waksal, M.D., President and CEO
Belumosudil: A Novel cGVHD Treatment

*Observed in KD025-208 and ROCKstar (KD025-213) Clinical Trials*

- **ROCK2 inhibitor** – novel dual modulator of inflammatory and fibrotic processes

- **Efficacy** – high response rates in advanced cGVHD patients

- **Safety** – well tolerated; 43% of patients have remained on treatment for 1 year¹

- **Improvement in QOL**

¹ KD025-208 follow-up data
Belumosudil (KD025) in cGVHD: Path Forward

- NDA submission for belumosudil (KD025) in cGVHD planned Q4 2020
  - Pre-NDA meeting with FDA took place in March 2020
  - Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program
  - FDA Breakthrough Therapy Designation and Orphan Drug Designation

- Belumosudil (KD025) has broad therapeutic potential beyond cGVHD, including:
  - Systemic sclerosis (Phase 2 clinical trial ongoing)
  - Bronchiolitis obliterans (BOS)
  - Other immune disorders
Q&A